Two Sigma Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Two Sigma Advisers’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-208,300	Closed	-$8.59M	–	1130
2025 Q4	$8.59M	Buy	208,300 +31,200	+18%	+$1.25M	0.02%	595
2025 Q3	$6.88M	Buy	177,100 +91,700	+107%	+$2.98M	0.01%	629
2025 Q2	$2.36M	Buy	+85,400	New	+$2.17M	﹤0.01%	1035
2021 Q3	–	Sell	-72,300	Closed	-$1.01M	–	2566
2021 Q2	$1.01M	Sell	72,300 -43,500	-38%	-$661K	﹤0.01%	1633
2021 Q1	$2.14M	Sell	115,800 -57,300	-33%	-$1.17M	0.01%	1232
2020 Q4	$3.06M	Sell	173,100 -26,100	-13%	-$458K	0.01%	1052
2020 Q3	$3.05M	Buy	199,200 +190,400	+2,164%	+$3.57M	0.01%	951
2020 Q2	$224K	Buy	+8,800	New	+$184K	﹤0.01%	2209

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Two Sigma Advisers's KNSA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 208,300 shares — an estimated $8.59M sold.

Two Sigma Advisers first reported a position in KNSA in Q2 2020 and held it in 8 quarters. The position peaked at $8.59M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Two Sigma Advisers reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 208,300 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $8.59M.
Two Sigma Advisers first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Two Sigma Advisers's Kiniksa Pharmaceuticals position peaked at $8.59M in Q4 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.